16 Apr, 2019 12:43 PM
SYDNEY, Australia, 16 April 2019: Imugene Limited (ASX:IMU), a clinical stage immuno-oncology company, is pleased to announce its Quarterly Cash Flow report (Appendix 4C) for the quarter ended 31 Marc...read more
16 Apr, 2019 10:05 AM
New class of immuno-oncology drug identified
Activator of NK cells and CD4+ immune cells
Potential to boost function of current immuno-oncology drugs.
SYDNEY, April 16, 2019: Noxopharm (AS...read more
15 Apr, 2019 04:25 PM
Following the expected release of the Appendix 4C on 18 April 2019, the Company will host a short briefing for investors and analysts at 10.00am (AEST).
For further information please download PD...read more
15 Apr, 2019 11:09 AM
Successful inaugural investor site visit to observe HPA plant construction progress
Stage 1 construction progress observed
Attendees included KfW IPEX-Bank, Macquarie Bank, CIMB...read more
15 Apr, 2019 11:05 AM
“We believe in building happy work places, being innovative, challenging the status quo and producing advanced materials for our future”
What is HPA?
Purified ...read more
15 Apr, 2019 10:02 AM
The securities of MMJ Group Holdings Limited (‘MMJ’) will be placed in trading halt at the request of MMJ, pending it releasing an announcement. Unless ASX decides otherwise, the securitie...read more